TIRZEPATIDE
(MOUNJARO / ZEPBOUND)
💬 Questions?
Have questions about Retatrutide or would like more information?
We’re happy to answer questions about our current inventory and provide additional information about our educational resources.
⚡ EXECUTIVE HIGHLIGHTS: THE GOLD STANDARD IN CLINICAL AGENTS
Are you exploring the absolute pinnacle of commercially available metabolic medicine? Tirzepatide is the world’s first approved dual GIP/GLP-1 receptor agonist, completely redefining real-world healthcare outcomes across diabetes and chronic weight management. [1, 2]
The >20% Weight Loss Standard: Clinical data establishes tirzepatide as a powerful option for body composition, with trial participants averaging a 20.9% to 25.3% reduction in total body weight. [1, 2]
Complete Glycemic Remission: In diabetes studies, up to 97% of patients successfully hit their target HbA1c goals, providing unrivaled therapeutic control over insulin and glucose. [1]
FDA-Approved Sleep Apnea Treatment: Tirzepatide is officially approved to treat moderate-to-severe Obstructive Sleep Apnea, slashing standard breathing disruptions by up to 63%. [1, 2, 3]
Heart Failure & MACE Protection: Recent large-scale trials demonstrate a 14% relative risk reduction in major adverse cardiac events, alongside a significant decrease in heart failure hospitalizations. [1, 2]
Rapid Fatty Liver Clearance: Clinical tracking shows a massive 40% to 80% reduction in liver fat content, making it a key focus for advanced liver disease treatments.
Ready to understand why this dual-acting powerhouse dominates the modern metabolic landscape? Read on to copy and paste the deep scientific details, landmark trial structures, and multi-disease indications behind tirzepatide. [1, 2]
COMPREHENSIVE RESEARCH INDICATIONS & CLINICAL TRIAL DIRECTORY
CHRONIC WEIGHT MANAGEMENT & OBESITY (FDA APPROVED) [1]
Research Focus: Evaluating systemic adiposity reduction, long-term weight maintenance, lean mass preservation, and metabolic health restoration. [1]
Key Clinical Program: SURMOUNT-1 through SURMOUNT-5. [1]
Key Milestones: In the primary 72-week SURMOUNT-1 trial, the highest 15 mg weekly dose achieved an average weight loss of 20.9%. Recent data tracking extended treatments showed that over 68% of patients maintained a ≥20% weight reduction out to 104 weeks. [1, 2, 3, 4]
Research Focus: Investigating glycemic control, hemoglobin A1c (HbA1c) lowering capacity, fasting glucose stability, and the preservation of pancreatic beta-cell function.
Key Clinical Program: SURPASS-1 through SURPASS-6.
Key Milestones: Across the SURPASS global pipeline, tirzepatide drove massive HbA1c reductions ranging from 1.8% to 2.4%. Head-to-head trials confirmed it significantly outperformed highest-dose single GLP-1 agonists (such as semaglutide 1 mg) in both blood sugar lowering and weight loss. [1, 2, 3, 4, 5]
OBSTRUCTIVE SLEEP APNEA (FDA APPROVED) [1]
Research Focus: Measuring the targeted reduction of airway collapses and nocturnal hypoxia (oxygen drops) to alleviate the need for continuous positive airway pressure (CPAP) therapy.
Key Clinical Program: SURMOUNT-OSA.
Key Milestones: This landmark trial revealed that tirzepatide reduced the Apnea-Hypopnea Index (AHI) by up to 62.8% (an average reduction of roughly 30 fewer breathing disruptions per hour), leading directly to its formal expanded FDA approval. [1, 2, 3, 4]
CARDIOVASCULAR OUTCOMES & HEART FAILURE
Research Focus: Tracking long-term reduction in Major Adverse Cardiovascular Events (MACE: heart attack, stroke, cardiovascular death) and evaluating treatment for Heart Failure with Preserved Ejection Fraction (HFpEF).
Key Clinical Program: SURPASS-CVOT and SUMMIT.
Key Milestones: In the SURPASS-CVOT trial tracking over 10,500 high-risk individuals, tirzepatide demonstrated a 14% relative risk reduction in composite MACE endpoints. The SUMMIT trial confirmed significant functional capacity improvements and reduced hospitalizations for heart failure patients. [1, 2, 3, 4, 5]
Research Focus: Investigating the resolution of "fatty liver," reductions in liver fat fraction via advanced imaging, and the slowing or structural reversal of hepatic fibrosis (scarring).
Key Clinical Program: SYNERGY-NASH.
Key Milestones: Phase 2 data revealed that up to 74% of participants achieved complete resolution of steatohepatitis without worsening liver scarring, positioning it as a leading therapeutic candidate for advanced Phase 3 liver protocols. [1, 2]
CHRONIC KIDNEY DISEASE (RENAL PROTECTION)
Research Focus: Evaluating changes in estimated glomerular filtration rate (eGFR), measuring reductions in kidney protein leakage (albuminuria), and tracking progression to end-stage renal disease.
Key Clinical Program: SURPASS-CVOT (Nested Renal Protocol) and TREASURE.
Key Milestones: Consolidated data shows tirzepatide users experience a significant slowdown in kidney function decline and a marked reduction in new-onset macroalbuminuria compared to standard basal insulins. [1, 2, 3]